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Abstract 
 
 
Introduction 
Campylobacteriosis, the most common bacterial foodborne illness, infects approximately 1.3 million 
people in the United States each year. Some Campylobacter infections have antimicrobial resistance to 
ciprofloxacin and erythromycin, which is a threat to public health given that physicians typically treat 
severe illnesses with these antimicrobial agents. 
 
Aims 
The objective of this study is to evaluate the change in incidence of Campylobacter over time and 
describe the trends in resistance to clinically significant antibiotics, including ciprofloxacin and 
erythromycin. This study will also compare hospitalizations and deaths among patients by resistance to 
clinically significant antibiotics. 
 
Methods 
A secondary analysis was performed using data from two Centers for Disease Control and Prevention 
(CDC) surveillance systems: Foodborne Diseases Active Surveillance (FoodNet) and National 
Antimicrobial Resistance Monitoring System (NARMS). We calculated the incidence of Campylobacter 
overall and by demographic characteristics for each year and compared resistance to ciprofloxacin and 
erythromycin in 2005 – 2012 and 2013 – 2017. Chi-Square and Fisher’s Exact tests were used to test 
differences in resistance over time by demographic characteristics and travel history. Lastly, we assessed 
health outcomes (hospitalizations and deaths) by antimicrobial susceptibility during 2005 – 2012 and 
2013 – 2017.  
 
Results 
 
During 2005 – 2017, incidence among culture-confirmed Campylobacter infections did not change 
substantially (12.71/100,000 persons in 2005 and 12.25/100,000 persons in 2017). The highest incidence 
was found in children younger than 5 years old: 25.24/100,000 persons in 2005 – 2008, 25.47/100,000 
persons in 2009 – 2012, 21.92/100,000 persons in 2013 – 2016, and 19.75/100,000 persons in 2017. 
Notably, males had a higher incidence compared to females across all years. Resistance to ciprofloxacin 
increased from 24% in 2005 – 2012 to 27% in 2013 – 2017, and resistance to erythromycin increased 
from 2% in 2005 – 2012 and 3% in 2013 – 2017.  Hospitalization was less likely in ciprofloxacin- and 
erythromycin-resistant cases than in ciprofloxacin- and erythromycin-susceptible cases, and results 
showed that only 1% of cases died due to infection, irrespective of antimicrobial susceptibility.  
 
Discussion 
The overall incidence and increase in resistance to first-line treatment antibiotics for Campylobacter 
infections remains a public health concern. The recent data used in our study highlight the importance of 
conducting Campylobacter surveillance and monitoring antimicrobial resistance.  
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INTRODUCTION 
Campylobacteriosis, one of the most common foodborne diseases, infects approximately 14 per 100,000 
persons or 1.3 million people in the United States each year (Scallan et al., 2011). An estimated 13,000 
hospitalizations and 120 deaths result from this bacterial diarrheal illness annually, among cases that 
were diagnosed and reported (Scallan et al., 2011). The majority of Campylobacter species are 
Campylobacter jejuni or coli, with C. jejuni causing approximately 90% of human infections and C. coli 
causing most of the remaining 10% (Bolinger & Kathariou, 2017). Causes of this illness most 
commonly include consumption of undercooked poultry, unpasteurized milk, contaminated water, or 
contact with infected animals (Taylor et al., 2013). Mild cases of illness can lead to hospitalization, 
while severe cases can lead to chronic conditions such as arthritis, irritable bowel syndrome (IBS), or 
Guillain-Barre syndrome (GBS) (Yuki & Hartung, 2012). 
Campylobacter is a self-limiting illness, therefore treatment is only recommended for children, elderly, 
immunocompromised patients, or patients with a prolonged infection (Allos, 2001). Physicians treat 
severe cases of illness with antibiotics erythromycin and ciprofloxacin due to their satisfactory clinical 
response (Engberg, Aarestrup, Taylor, Gerner-Smidt, & Nachamkin, 2001). However, the overuse of 
antibiotics in humans is increasing antimicrobial resistance to these antibiotics and may lead to rising 
trends in Campylobacter infections over time (Payot et al., 2006). 
A recent paper by Geissler et al. used national case data from FoodNet sites to estimate incidence rates 
of culture-confirmed Campylobacter cases in the United States during 2004-2012. Their research 
findings indicated that the average incidence was 11.4 cases/100,000 persons, although there was some 
variation in incidence geographically and demographically (Geissler et al., 2017). Researchers also 
found that incidence was highest among children 4 years old and younger (26.3 cases/100,000 persons), 
which is concerning for public health (Geissler et al., 2017). Nearly a quarter of isolates (23.4%) were 
resistant to ciprofloxacin and 2.1% of isolates were resistant to erythromycin. The number of 
Campylobacter infections with antimicrobial resistance to first-line treatment antibiotics highlighted the 
importance of continuing to monitor resistance trends and incidence rates.  
We assessed Campylobacter data to evaluate the trends in infections in the U.S. reported between 2005 
and 2017. We build on the work by Geissler et al. by updating incidence estimates and describing recent 
trends in resistance to clinically-significant antibiotics, including ciprofloxacin and erythromycin. 
Additionally, we compare health outcomes (i.e. the number of hospitalizations and deaths) of recent 
years to earlier years in order to describe the public health impact that this foodborne illness is having on 
the population.  
METHODS 
Data Sources  
Data were retrieved from two Centers for Disease Control and Prevention (CDC) data systems: the 
Foodborne Diseases Active Surveillance Network (FoodNet) and National Antimicrobial Resistance 
Monitoring System (NARMS). FoodNet is a population-based, active surveillance system that 
collaborates with the U.S. Department of Agriculture’s Food Safety Inspection Service (USDA-FSIS), 
the U.S. Food and Drug Administration (FDA) to collect epidemiological data on foodborne infections 
related to Campylobacter, Listeria, Salmonella, Shiga toxin-producing Escherichia coli (STEC) O157, 
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Shigella, Vibrio, and Yersinia. The FoodNet catchment area includes Connecticut, Georgia, Maryland, 
Minnesota, New Mexico, Oregon, Tennessee and select counties in California, Colorado, and New 
York. These 10 sites are a representative sample of 15% of the U.S. population. Data collected through 
these programs are significant as they provide patient demographic, travel history, and clinical data for 
laboratory-confirmed cases, which is used to analyze disease burden.  
NARMS is an isolate-based, passive surveillance system that collaborates with USDA-FSIS, FDA, and 
54 sites in the U.S. to test Campylobacter, Shigella, E. coli O157, and Vibrio. For Campylobacter, 
NARMS only has programs in the respective 10 FoodNet sites. Isolates sent to NARMS include basic 
patient demographic and bacterial data for antimicrobial agents. As mentioned previously, this research 
will only investigate antimicrobial susceptibility to the two first-line antibiotics used to treat 
Campylobacter, ciprofloxacin and erythromycin.  
Data Analysis 
Data from the NARMS and FoodNet surveillance systems were merged using state laboratory IDs to 
assess the epidemiology and antimicrobial resistance of Campylobacter infections. A total of 80,495 
culture-confirmed cases were found in the FoodNet database during 2005-2017. The NARMS database 
had 16,276 laboratory-approved isolates, in which approximately 85% successfully linked to a single 
case in the FoodNet database. After applying inclusion criteria to only include Campylobacter species 
coli and jejuni, NARMS lab-approval, and years 2005-2017, the total analytic sample included 13,454 
cases.  
First, we estimated incidence of Campylobacter by demographic characteristics of all culture-confirmed 
cases included in FoodNet during four time periods: 2005-2008, 2009-2012, 2013-2016 and 2017. We 
imputed missing values for race by distributing missing values to observed proportions of 
Campylobacter infections by race. All rates were calculated per 100,000 persons in the United States 
and were divided using population data retrieved from the most recent U.S. Census (U.S. Census 
Bureau, 2018).  
Next, using isolates in the linked dataset, we compared resistance to ciprofloxacin and erythromycin 
during 2005-2012 and 2013-2017. Characteristics assessed in this analysis included demographic factors 
(i.e. age, sex, and race) as well as patient’s travel history. Chi-Square tests were used to statistically test 
differences in resistance by year groupings (p < .05). A Fisher’s Exact test supplemented the Chi-Square 
test when cells were less than 5. Last, we described health outcomes (hospitalizations and deaths) by 
antimicrobial susceptibility for antimicrobial agents ciprofloxacin and erythromycin during 2005-2012 
and 2013-2017.  
All statistical analyses and data merging were performed in SAS software version 9.4. Chi-Square and 
Fisher’s Exact test were used to analyze if changes in antimicrobial resistance for more recent years 
were statistically significantly different compared to earlier years.    
RESULTS 
Demographics  
Among the population of Campylobacter cases, 41% were between 30-59 years old and 19% were 60 
years or older (Note: percentages not shown in table). There were more males (55%) than females 
(45%), and 66% of cases self-reported as White race. The state of residence varied; however, this is 
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expected as population sizes vary across years. An estimated 8% reported international travel within 
seven days of illness onset.   
Incidence  
The incidence among culture-confirmed cases has remained fairly stable over the 13-year period, with 
an incidence of 12.71/100,000 persons in 2005 and 12.25/100,000 persons in 2017. The overall 
incidence in 2005 – 2008 was 12.72/100,000 persons, 13.75/100,000 persons in 2009 – 2012, 
12.91/100,000 persons in 2013 – 2016, and 12.25/100,000 persons in 2017. The highest incidence 
occurred in years 2009 – 2012. 
By age, children between ages 0 and 4 years old had the highest incidence: 25.24/100,000 persons in 
2005 – 2008, 25.47/100,000 persons in 2009 – 2012, 21.92/100,000 persons in 2013 – 2016, and 
19.75/100,000 persons in 2017. Across all year groups, males had a higher incidence than females. 
Based on imputed values for race, American Indian or Alaskan Natives had the highest incidence in 
2005 – 2008 (25.23/100,000 persons), 2009 – 2012 (17.88/100,000 persons), and 2017 (16.62/100,000 
persons). In 2013 – 2016, Whites had a higher incidence (14.56/100,000 persons) than the American 
Indian and Alaskan Natives (Table 1).  
Table 1. Incidence rates of Culture-Confirmed Campylobacter Infections, 2005-2017 
*Data shown are based on true counts before imputation of unknown data. 
 
 
  2005-2008 2009-2012 2013-2016 2017 
Characteristic N =  
23, 192 
Incidence 
per 
100,000 
N = 
26,036 
Incidence 
per 
100,000 
N = 
25,175 
Incidence 
per 
100,000 
N = 
6,092 
Incidence 
per 
100,000 
AGE, in years 
        
0-4 
5-9 
10-19 
20-29 
30-59 
60+ 
Unknown 
3039 
1222 
2186 
3226 
10039 
3467 
13 
25.24 
10.30 
8.52 
13.02 
12.98 
11.34 
 
3071 
1323 
2366 
3752 
10616 
4895 
13 
25.47 
10.76 
9.27 
14.45 
13.52 
14.00 
 
2591 
1095 
2133 
3671 
10226 
5457 
2 
21.92 
8.86 
8.45 
13.61 
12.93 
13.75 
 
584 
253 
513 
857 
2448 
1437 
19.75 
8.28 
8.08 
12.50 
12.34 
13.44 
 
SEX 
        
Male 
Female 
Unknown 
12,733 
10,441 
18 
14.24 
11.24 
 
14,280 
11,737 
19 
15.38 
12.17 
 
13,756 
11,393 
26 
14.36 
11.46 
 
3279 
2808 
5 
13.43 
11.09 
 
RACE* 
        
Asian (includes Pacific Islander or Native Hawaiian) 
Black 
American Indian or Alaskan Native 
Multiracial 
White 
Other 
808 
898 
378 
93 
14394 
381 
12.89 
4.34 
25.23 
3.61 
14.09 
 
968 
1041 
307 
162 
16502 
647 
13.09 
4.57 
17.88 
4.95 
15.34 
 
1023 
1174 
284 
159 
17832 
825 
10.76 
4.36 
13.89 
3.80 
14.56 
 
309 
336 
93 
60 
4388 
276 
11.28 
4.55 
16.62 
5.02 
13.41 
 
STATE OF RESIDENCE 
        
California 
Colorado 
Connecticut 
Georgia 
Maryland 
Minnesota 
New Mexico 
New York 
Oregon 
Tennessee 
3699 
1783 
2098 
2537 
1627 
3533 
1442 
2030 
2670 
1773 
28.56 
16.95 
14.88 
6.87 
7.21 
17.04 
18.26 
11.75 
18.07 
7.24 
4406 
1587 
2323 
2775 
2183 
3852 
1316 
2416 
3418 
1760 
32.42 
14.06 
16.21 
7.11 
9.39 
18.07 
15.93 
13.95 
22.19 
6.90 
3160 
1410 
2727 
2568 
2730 
3712 
1398 
2610 
3204 
1656 
21.96 
11.61 
18.96 
6.33 
11.41 
16.97 
16.77 
15.12 
20.05 
6.30 
800 
301 
508 
616 
661 
1049 
478 
599 
629 
451 
21.65 
9.55 
14.16 
5.91 
10.92 
18.81 
22.89 
13.92 
15.18 
6.72 
Average overall incidence  12.72 13.75 12.91 12.25 
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Antimicrobial Resistance 
Of isolates that could be linked to a FoodNet case, there were 3,344 ciprofloxacin-resistant and 357 
erythromycin-resistant isolates in NARMS during 2005 – 2017. Resistance to ciprofloxacin steadily 
increased over the years, with 29% of isolates conferring resistance to ciprofloxacin in 2017. During 
2013-2017, 1451 (27%) of isolates were ciprofloxacin-resistant and 187 (3%) were erythromycin-
resistant (Table 2). Compared to the earlier years (2005-2012), the increase in resistance to both 
antibiotics were statistically significant. 
Resistance to ciprofloxacin increased over time among people under 30 years old, males, females, 
Whites, travel-associated and non-travel associated cases (Table 2). Resistance to erythromycin 
increased over time among people 30 years and older, males, females, Multiracial, Whites, and non-
travel associated acquired cases for erythromycin-resistant cases (Table 2). 
Table 2. Characteristics by antibiotic drug resistance, 2005-2017 
*Statistical significance is defined as p < .05 
Health Outcomes 
During 2013-2017, 179 (13%) patients with a ciprofloxacin-resistant Campylobacter infection were 
hospitalized, compared to 746 (19%) of patients with ciprofloxacin-susceptible Campylobacter 
infections (Table 3). These findings are comparable to those in the earlier years, with 214 (12%) of 
resistant cases and 979 (17%) of susceptible cases being hospitalized (Table 3). As shown in Table 3, 
mortality associated with a Campylobacter infection is less than 1% among persons with both resistant 
and susceptible Campylobacter infections.  
 
 
 
  
  
  
Ciprofloxacin-Resistant P-value 
 
Erythromycin-Resistant P-value 
2005-2012 2013-2017 2005-2012 2013-2017 
AGE, (YEARS) n (%) n (%) n (%) n (%) 
0-4  
5-9 
10-19 
20-29 
30-59 
60+ 
143 (14%) 
64 (15%) 
160 (21%) 
321 (28%) 
904 (27%) 
301 (22%) 
118 (21%) 
51 (21%) 
139 (30%) 
259 (33%) 
624 (29%) 
260 (22%) 
0.0009* 
0.0472* 
0.0006* 
0.0216* 
0.1795 
0.7778 
7 (1%) 
5 (1%) 
11 (1%) 
34 (3%) 
90 (3%) 
23 (2%) 
9 (2%) 
3 (1%) 
14 (3%) 
36 (5%) 
82 (4%) 
43 (4%) 
0.093 
0.9407 
0.0631 
0.0638 
0.0242* 
0.0026* 
SEX 
Male 
Female 
 
1034 (23%) 
857 (24%) 
 
773 (26%) 
674 (27%) 
 
0.0031* 
0.0043* 
 
87 (2%) 
82 (2%) 
 
92 (3%) 
95 (4%) 
 
.0014* 
.0005* 
RACE* 
Asian (includes Pacific Islander or Native Hawaiian) 
Black 
American Indian or Alaskan Native 
Multiracial 
White 
Other 
Unknown 
 
78 (37%) 
101 (26%) 
14 (11%) 
10 (23%) 
1221 (22%) 
26 (28%) 
443 (27%) 
 
60 (34%) 
56 (22%) 
13 (13%) 
13 (39%) 
1078 (26%) 
42 (29%) 
189 (34%) 
 
0.5221 
0.2943 
0.6711 
0.129 
<.0001* 
0.8547 
0.0039* 
 
5 (2%) 
8 (2%) 
1 (1%) 
0 (0%) 
124 (2%) 
2 (2%) 
30 (2%) 
 
7 (4%) 
10 (4%) 
1 (1%) 
3 (9%) 
127 (3%) 
4 (3%) 
35 (6%) 
 
0.3708 
0.1499 
0.8715 
0.0437* 
0.0121* 
0.7675 
<.0001* 
TRAVEL-ASSOCIATED 
Yes 
No 
 
658 (63%) 
688 (15%) 
 
561 (75%) 
701 (18%) 
 
<.0001* 
<.0001* 
 
48 (5%) 
71 (2%) 
 
43 (6%) 
123 (3%) 
 
0.2645 
<.0001* 
TOTAL 1893 (24%) 1451 (27%) 
 
170 (2%) 187 (3%)  
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Table 3. Health outcomes by ciprofloxacin susceptibility, 2005-2017 
  
  
  
Ciprofloxacin 
2005-2012 2013-2017 
Resistant Susceptible Resistant Susceptible 
Total 1893 (24%) 6134 (76%) 1451 (27%) 3976 (73%) 
HOSPITILIZATION 
    
  Yes 
  No 
214 (12%) 
1592 (88%) 
979 (17%) 
4924 (83%) 
179 (13%) 
1230 (87%) 
746 (19%) 
3133 (81%) 
OUTCOME 
    
   Alive 
   Dead 
1706 (99.8%) 
3 (0.2%) 
5631 (99.9%) 
3 (0.1%) 
1422 (100%) 
0 (0%) 
3903 (99.9%) 
6 (0.1%) 
 
Patients with either an erythromycin-resistant or erythromycin-susceptible Campylobacter infection 
were slightly more likely to be hospitalized in the more recent years (17% and 18% hospitalized during 
2013 – 2017 among patients with resistant and susceptible infections, respectively) (Table 4). There was 
a higher proportion of hospitalization among the erythromycin-resistant cases compared to the 
ciprofloxacin-resistant cases. Regardless of the susceptibility to erythromycin status, mortality due to 
Campylobacter infection is less than 1% (Table 4).  
Table 4. Health outcomes by erythromycin susceptibility, 2005-2017 
  
  
  
Erythromycin 
2005-2017 2013-2017 
Resistant Susceptible Resistant Susceptible 
Total 170 (2%) 7857 (98%) 187 (3%) 5280 (97%) 
HOSPITILIZATION 
    
   Yes 
   No 
23 (14%) 
144 (86%) 
1170 (16%) 
6372 (84%) 
31 (17%) 
150 (83%) 
894 (18%) 
4213 (82%) 
OUTCOME 
    
   Alive 
   Dead 
157 (100%) 
0 (0%) 
7180 (99.9%) 
6 (0.1%) 
181 (99.5%) 
1 (0.5%) 
5144 (99.9%) 
5 (0.1%) 
 
DISCUSSION 
The incidence for culture-confirmed cases of Campylobacter remained relatively stable between 2005 
and 2017. Consistent with previous literature, findings showed that children under 5 years old and males 
had the highest incidence of Campylobacter infections (Geissler et al., 2017). American Indian and 
Alaskan Natives had a higher incidence compared to all other racial groups, which has also been found 
previously (Geissler et al., 2017). 
Resistance to clinically-significant antibiotics ciprofloxacin and erythromycin increased during 2005 – 
2017. In travel-associated cases, resistance to ciprofloxacin increased from 63% to 75% between 2005 – 
2012 and 2013 – 2017, while resistance to erythromycin increased from 5% to 6% between 2005 – 2012 
and 2013 – 2017. These findings were based on complete case data, and data on recent travel were 
missing for 54% of cases.  Previous studies also show that more than half of international travel-
associated cases involve ciprofloxacin-resistant Campylobacter infections (Geissler et al., 2017; Ricotta 
et al., 2014). Education about risks and preventative measures should be taken to reduce the number of 
antimicrobial resistant Campylobacter infections among international travelers. 
We observed a higher percentage of hospitalizations among the susceptible cases, which may be 
partially confounded by young adult age (20-29 years) or “healthy traveler effects,” both of which are 
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negatively associated with hospitalization and positively associated with having a resistant infection. 
Previous research has shown that traveling can positively impact your health and decrease the likelihood 
or hospitalization or mortality due to a diarrheal infection (Ricotta et al., 2014). This is known as the 
“healthy traveler effect” (Ricotta et al., 2014).  
There were a few limitations to this study, some of which were related to the surveillance systems used. 
As mentioned previously, the FoodNet data system includes 10 sites or state health departments in the 
United States. The FoodNet surveillance systems collects quality data that is representative of the entire 
country; however, the surveillance only covers 15% of the U.S. leaving the potential for some trends not 
being captured. Additionally, the FoodNet data analyzed only included Campylobacter with culture-
confirmed cases. In other words, these data excluded any case without a culture or cases diagnosed using 
culture-independent diagnostic testing (CIDT). The technological advancement of CIDTs aids in faster 
detection and diagnosis of infection, however these tests do not provide enough information to capture 
incidence. 
Another limitation was the variation in Campylobacter sampling. The different sampling schemes in 
FoodNet sites impacts the number of isolates shipped to CDC NARMS laboratory for testing. Due to the 
inconsistent number of isolates shipped to CDC, only a subset of antimicrobial susceptibility testing 
(AST) results were available. Isolates with finalized results were linked to FoodNet cases. Lastly, 
analyses were limited to Campylobacter jejuni and coli because there currently are no breakpoints 
interpretations established for other Campylobacter species.  
One of the advantages of this study is that it adds to previous literature around this topic with use of 
more current data. Although incidence has remained steady over the years, an increase in antimicrobial 
resistance to first-line treatment antibiotics remain a public health concern. This study also reiterates the 
importance of ordering Campylobacter cultures. Surveillance data from studies such as this keeps 
treatment guidelines up-to-date and informs physicians on how to treat individual cases of 
Campylobacter infections using antimicrobial agents. 
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